

Kiadis Pharma announces appointment of Mark Skaletsky to its Supervisory Board

Amsterdam, December 11, 2008 – Oncology focused biopharmaceutical product development company Kiadis Pharma announces today that Mark Skaletsky was elected to its Supervisory Board as an independent board member.

Manja Bouman, Chief Executive Officer, says: *"I am very pleased that Mark Skaletsky joins the supervisory board of Kiadis Pharma. He has a long and impressive career as a senior executive with several successful biopharmaceutical companies. His input will be invaluable as we prepare for the next steps in the development of our products."*

"I am excited to have the opportunity to join Kiadis Pharma's Supervisory Board. I believe I am joining the company at a very exciting time with its lead product ATIR™ ready to move into a pivotal study," says Mark Skaletsky. *"Kiadis Pharma has unique products in development that have the potential to fulfill a high unmet medical need, specifically for patients in need of a bone marrow transplantation, and I look forward to assisting the company as it advances."*

Mr. Skaletsky has a long outstanding track record within the biotech industry. He served as president and CEO of GelTex Pharmaceuticals, Inc. (acquired by Genzyme for more than \$1 billion in December 2000), chairman and CEO of Enzytech, Inc., and president and Chief Operating Officer of Biogen, Inc. He is also a former chairman of the board of directors of the Biotechnology Industry Organization (BIO). Mr. Skaletsky is chairman, CEO and president of Fenway Pharmaceuticals, Inc.

About Kiadis Pharma

Kiadis Pharma is an oncology focused pharmaceutical development company with three products in different phases of clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address significant unmet medical needs. The key focus indication for Kiadis Pharma is limitations and complications of bone marrow transplantation procedures performed in blood cancer patients. Kiadis Pharma is headquartered in Amsterdam, The Netherlands with facilities in Groningen, The Netherlands and Montreal, Canada. For more information about Kiadis Pharma, please visit www.kiadis.com.

For more information please contact:

Kiadis Pharma B.V.

Eefje Simpelaar

Director Communications

Email: e.simpelaar@kiadis.com

Tel: +31 20 3140250

Mob +31 6 10829344